Document is current
Any future updates will be listed below
-
Authors
Body, Amy https://orcid.org/0000-0002-0601-8485
Ahern, Elizabeth
Lal, Luxi
Gillett, Karen
Abdulla, Hesham
Opat, Stephen
O’Brien, Tracey
Downie, Peter
Turville, Stuart
Munier, C. Mee Ling
Smith, Corey
MacIntyre, C. Raina
Segelov, Eva
-
Clinical Trials BETA
Clinical trials referenced in this document:
actrn12621001004853 at Australian New Zealand Clinical Trials RegistryDocuments that mention this clinical trial
Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)
https://doi.org/10.1186/s12879-021-07019-1
-
Funding
Funding for this research was provided by:
Cancer Australia (COMMONWEALTH APPROACH TO MARKET (ATM) REFERENCE NO. F21/113)
Leukaemia Foundation
Department of Health and Human Services, State Government of Victoria
- License Information
-
More Information
Article History
Received: 21 December 2021
Accepted: 24 December 2021
First Online: 20 January 2022
Declarations
:
: SerOzNET study is performed according to the Declaration of Helsinki and the National Health and Medical Research Council (Australia) Statement on Ethical Conduct in Human Research (2018). Multisite ethics approval was granted by the lead site Human Research Ethics Committee, Monash Health (HREC/76506/MonH-2021-268415) prior to study commencement. Written informed consent according to Good Clinical Practice principles is given by each participant prior to the commencement of any study activities, or in the case of children, by their legal guardian.
: Not applicable.
: RM has consulted for or been on advisory boards for Seqirus, AstraZeneca and Janssen on COVID-19 vaccines. She has been a panellist on a WHO research and development consultation on COVID-19 vaccines.
